The Hairy Cell Leukemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hairy Cell Leukemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued products.
GlobalData tracks 29 drugs in development for Hairy Cell Leukemia by 25 companies/universities/institutes. The top development phase for Hairy Cell Leukemia is phase i with 11 drugs in that stage. The Hairy Cell Leukemia pipeline has 23 drugs in development by companies and six by universities/ institutes. Some of the companies in the Hairy Cell Leukemia pipeline products market are: F. Hoffmann-La Roche, Incyte and Novartis.
The key targets in the Hairy Cell Leukemia pipeline products market include B Lymphocyte Antigen CD19, B Cell Receptor CD22, and B Lymphocyte Antigen CD20.
The key mechanisms of action in the Hairy Cell Leukemia pipeline product include Serine/Threonine Protein Kinase B Raf Inhibitor with three drugs in Phase II. The Hairy Cell Leukemia pipeline products include five routes of administration with the top ROA being Oral and seven key molecule types in the Hairy Cell Leukemia pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.
Hairy Cell Leukemia overview
Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness, and weight loss. Risk factors include exposure to radiation, chemicals, and saw dust. Treatment includes surgery, chemotherapy, and radiation therapy.
For a complete picture of Hairy Cell Leukemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
